There have been tremendous advances in targeted biological therapies for asthma and allergies over the past 20 years, and your Snö team has experience and expertise in determining if any of these may be appropriate for you or your child.
Anti-IgE therapy (omalizumab)
Omalizumab is a monoclonal antibody therapy proven effective for moderate-to-severe asthma in patients > 6 years of age, or for patients with chronic urticaria (hives) > 12 years of age. It has also shown promising results in patients undergoing OIT for food allergies. This biological agent has been in wide use for nearly 20 years, and your allergist will be able to determine if this is a good option for you.
Anti-IL5 therapies (mepolizumab, reslizumab, benralizumab)
These newer biological anti-IL5 or anti-eosinophil agents have been shown to be particularly effective in severe difficult-to-control allergic or eosinophilic asthma. They each have their own potential advantages, and your allergist will be able to help decide if one of these agents is right for you.
Anti-IL4 therapy (dupilumab)
Dupilumab is a novel anti-IL4 antibody which has been proven effective for severe persistent atopic dermatitis (eczema), and has also shown promising results for severe asthma, both allergic/eosinophilic and not. The Snö Asthma & Allergy team will help determine if you are a candidate for this newer treatment option.